Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2023-174652

Published: 2023

Journal Articles

Preclinical and Early Clinical Results Indicate a Role for the Oral p300/CBP Inhibitor Inobrodib (CCS1477) in T-Cell Lymphoma

Victoria Campbell, Harriet Walter, Adam Gibb, Andrew S. Davies, Nagah Elmusharaf, Neil Pegg, Will Henry West, Tomasz Knurowski, Kris Frese, Debbie Haynes, Karen Clegg, Tim Somervaille

Blood (2023) 142 (Supplement 1): 5795.

https://doi.org/10.1182/blood-2023-187378

Published: 2023

Journal Articles

Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma

Luciano Nicosia, Nigel Brooks, Fabio Amaral, Oliver Sinclair, Neil A Pegg, William West, Tomasz Knurowski, Kris Frese, Karen Clegg, James Cavet, Emma Searle, Tim C.P Somervaille

Blood (2022) 140 (Supplement 1): 852–853.

https://doi.org/10.1182/blood-2022-157535

Published: 2022

Journal Articles

Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 8774–8775.

https://doi.org/10.1182/blood-2022-166260

Published: 2022